Sickle Cell Disease Treatment Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	103 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19260648

Best Price Guarantee
Price	from $4,850
Length	103 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19260648

Sickle Cell Disease Treatment Market

Growth Factors of Sickle Cell Disease Treatment Market

The Sickle cell disease treatment market size was valued at USD 2.25 billion in 2022, and the market is now projected to grow from USD 2.73 billion in 2023 to USD 9.18 billion by 2030, exhibiting a CAGR of 20.1% during the forecast period of 2023-2030.

The global COVID-19 pandemic had no influence on the aspects of the pharmacotherapy segment of the market since the sales of branded treatment pharmaceutical medication progressed from 2019 to 2020. The sustainability of this segment was achieved through the continuing provision of patient access to needed therapies. Moreover, legitimate supply chains made it possible to exclude interruptions in the delivery of medications during the pandemic. As such, the need for pharmacotherapy remained strong, even with the pandemic taking over the world.

They increased the number of cases of sickle cell disease victims that stands at millions of individuals worldwide. This Shoe increasing incidence is contributing to market growth as the healthcare institutions continue to look for proper treatments and therapies. Expanding recognition of sickle cell disease also fuels R&D activities to respond to the market demands of patients. For this reason, the need for new approaches in the management and treatment of this ailment will remain high.

The use of gene therapy has progressively become innovative treatment for chronic diseases especially the inherited ones since it goes to the source of the problem. This creative strategy is to bring changes to the nucleotide sequence that are related to these diseases, therefore, long term treatments. Therefore, it has been observed that market players have increased the concentration on researching and developing new techniques of gene therapy. A higher level of investment in this sector is encouraging due to the acknowledgment that gene therapy offers great promise for changing the approach to treatment.

Comprehensive Analysis of Sickle Cell Disease Treatment Market

The Sickle cell disease treatment market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly presents a detailed local analysis based on the forces such as supply and demand which define the industry. These segmentations are methodically segregated by treatment modality analysis, and by end-user analysis. By treatment modality analysis include blood transfusion, bone marrow transplant, and pharmacotherapy. By end-user analysis include hospitals, specialty clinics, and others.

The U.S. region lead the Sickle cell disease treatment market share by benefitting a market size of USD 1.44 billion in 2023 due to strong government support.

The top players have a significant responsibility in the healthcare industry for confirming industrial prospectus growth and determining the market trends. These players include Bristol-Myers Squibb Company, Addmedica, Novartis AG, Global Blood Therapeutics, Inc. (Pfizer Inc.), Emmaus Medical, Inc., bluebird bio-Inc., Agios Pharmaceuticals, Inc. these market players provide a level-playing competitive landscape.

In March 2023, AddMedica ties up with Abacus Medicine Pharma Services for marketing of Siklos (hydroxyurea) in Belgium Netherlands & Luxembourg, for patients aged 2 years and above.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Growth Rate CAGR of 20.1% from 2023-2030

Unit Value (USD Billion)

Segmentation By Treatment Modality, End-user, and Geography

By Treatment Modality Bone Marrow Transplant

Blood Transfusion

Pharmacotherapy

Hydroxyurea
Branded Products

- Endari

- Adakveo

- Oxbryta

- Zynteglo

- PYRUKYND (Mitapivat)

- CTX001

- Inclacumab

- MGTA-145

- Vamifeport (VIT-2763)

- ALXN1820

- FT-4202

- GBT021601

By End-user

Hospitals

Specialty Clinics

Others

By Geography U.S. (By Treatment Modality and End-user)

Europe (By Treatment Modality, End-user, and Country/Sub-region)

Germany
U.K.
France
Italy
Spain
Scandinavia
Rest of Europe

Rest of the World (By Treatment Modality, End-user, and Country/Sub-region)

India
China
Japan
GCC Countries
Rest of ROW

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Prevalence of Sickle Cell Disease, For Key Countries/ Regions, 2022; 4.2. Overview – Branded Drugs (Marketed); 4.3. Pipeline Analysis, Key Players; 4.4. New Product Launches; 4.5. Key Industry Developments (Mergers, Acquisitions, Partnership; etc.); 4.6. Impact of COVID-19 on the Market
5. Global Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2019-2030: 5.1. Market Analysis, Insights and Forecast – By Treatment Modality; 5.1.1. Bone Marrow Transplant; 5.1.2. Blood Transfusion; 5.1.3. Pharmacotherapy; 5.1.3.1. Hydroxyurea; 5.1.3.2. Branded Products; 5.1.3.2.1. Endari; 5.1.3.2.2. Adakveo; 5.1.3.2.3. Oxbryta; 5.1.3.2.4. PYRUKYND (Mitapivat); 5.1.3.2.5. Zynteglo; 5.1.3.2.6. CTX001; 5.1.3.2.7. Inclacumab; 5.1.3.2.8. Vamifeport (VIT-2763); 5.1.3.2.9. ALXN1820; 5.1.3.2.10. MGTA-145; 5.1.3.2.11. FT-4202; 5.1.3.2.12. GBT021601; 5.2. Market Analysis, Insights and Forecast – By End-user; 5.2.1. Hospitals; 5.2.2. Specialty Clinics; 5.2.3. Others; 5.3. Market Analysis, Insights and Forecast – By Country/Region; 5.3.1. U.S.; 5.3.2. Europe; 5.3.3. Rest of the World
6. U.S. Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2019-2030: 6.1. Market Analysis, Insights and Forecast – By Treatment Modality; 6.1.1. Bone Marrow Transplant; 6.1.2. Blood Transfusion; 6.1.3. Pharmacotherapy; 6.1.3.1. Hydroxyurea; 6.1.3.2. Branded Products; 6.1.3.2.1. Endari; 6.1.3.2.2. Adakveo; 6.1.3.2.3. Oxbryta; 6.1.3.2.4. PYRUKYND (Mitapivat); 6.1.3.2.5. Zynteglo; 6.1.3.2.6. CTX001; 6.1.3.2.7. Inclacumab; 6.1.3.2.8. Vamifeport (VIT-2763); 6.1.3.2.9. ALXN1820; 6.1.3.2.10. MGTA-145; 6.1.3.2.11. FT-4202; 6.1.3.2.12. GBT021601; 6.2. Market Analysis, Insights and Forecast – By End-user; 6.2.1. Hospitals; 6.2.2. Specialty Clinics; 6.2.3. Others
7. Europe Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2019-2030: 7.1. Market Analysis, Insights and Forecast – By Treatment Modality; 7.1.1. Bone Marrow Transplant; 7.1.2. Blood Transfusion; 7.1.3. Pharmacotherapy; 7.1.3.1. Hydroxyurea; 7.1.3.2. Branded Products; 7.1.3.2.1. Endari; 7.1.3.2.2. Adakveo; 7.1.3.2.3. Oxbryta; 7.1.3.2.4. PYRUKYND (Mitapivat); 7.1.3.2.5. Zynteglo; 7.1.3.2.6. CTX001; 7.1.3.2.7. Inclacumab; 7.1.3.2.8. Vamifeport (VIT-2763); 7.1.3.2.9. ALXN1820; 7.1.3.2.10. MGTA-145; 7.1.3.2.11. FT-4202; 7.1.3.2.12. GBT021601; 7.2. Market Analysis, Insights and Forecast – By End-user; 7.2.1. Hospitals; 7.2.2. Specialty Clinics; 7.2.3. Others
8. Rest of the World Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2019-2030: 8.1. Market Analysis, Insights and Forecast – By Treatment Modality; 8.1.1. Bone Marrow Transplant; 8.1.2. Blood Transfusion; 8.1.3. Pharmacotherapy; 8.1.3.1. Hydroxyurea; 8.1.3.2. Branded Products; 8.1.3.2.1. Endari; 8.1.3.2.2. Adakveo; 8.1.3.2.3. Oxbryta; 8.1.3.2.4. PYRUKYND (Mitapivat); 8.1.3.2.5. Zynteglo; 8.1.3.2.6. CTX001; 8.1.3.2.7. Inclacumab; 8.1.3.2.8. Vamifeport (VIT-2763); 8.1.3.2.9. ALXN1820; 8.1.3.2.10. MGTA-145; 8.1.3.2.11. FT-4202; 8.1.3.2.12. GBT021601; 8.2. Market Analysis, Insights and Forecast – By End-user; 8.2.1. Hospitals; 8.2.2. Specialty Clinics; 8.2.3. Others
9. Competitive Analysis: 9.1. Global Market Share Analysis (2022); 9.2. Company Profiles; 9.2.1. Bristol-Myers Squibb Company; 9.2.1.1. Overview; 9.2.1.2. Product; 9.2.1.3. SWOT Analysis; 9.2.1.4. Recent Developments; 9.2.1.5. Strategies; 9.2.1.6. financials (Based on Availability); 9.2.2. Addmedica; 9.2.2.1. Overview; 9.2.2.2. Product; 9.2.2.3. SWOT Analysis; 9.2.2.4. Recent Developments; 9.2.2.5. Strategies; 9.2.2.6. financials (Based on Availability); 9.2.3. Novartis AG; 9.2.3.1. Overview; 9.2.3.2. Product; 9.2.3.3. SWOT Analysis; 9.2.3.4. Recent Developments; 9.2.3.5. Strategies; 9.2.3.6. financials (Based on Availability); 9.2.4. Global Blood Therapeutics, Inc. (Pfizer Inc.); 9.2.4.1. Overview; 9.2.4.2. Product; 9.2.4.3. SWOT Analysis; 9.2.4.4. Recent Developments; 9.2.4.5. Strategies; 9.2.4.6. financials (Based on Availability); 9.2.5. Emmaus Medical, Inc.; 9.2.5.1. Overview; 9.2.5.2. Product; 9.2.5.3. SWOT Analysis; 9.2.5.4. Recent Developments; 9.2.5.5. Strategies; 9.2.5.6. financials (Based on Availability); 9.2.6. bluebird bio Inc.; 9.2.6.1. Overview; 9.2.6.2. Product; 9.2.6.3. SWOT Analysis; 9.2.6.4. Recent Developments; 9.2.6.5. Strategies; 9.2.6.6. financials (Based on Availability); 9.2.7. Agios Pharmaceuticals, Inc.; 9.2.7.1. Overview; 9.2.7.2. Product; 9.2.7.3. SWOT Analysis; 9.2.7.4. Recent Developments; 9.2.7.5. Strategies; 9.2.7.6. financials (Based on Availability)